144 related articles for article (PubMed ID: 9488603)
61. Cisplatin and etoposide in chemotherapy-refractory advanced breast cancer.
Giaccone G; Donadio M; Ferrati P; Calciati A
Tumori; 1988 Apr; 74(2):191-3. PubMed ID: 3368973
[TBL] [Abstract][Full Text] [Related]
62. Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.
Hoffmann W; Weidmann B; Migeod F; Könner J; Seeber S
Cancer Chemother Pharmacol; 1990; 26 Suppl():S69-70. PubMed ID: 2347053
[TBL] [Abstract][Full Text] [Related]
63. The role of lonidamine in the treatment of breast cancer patients.
Rosso R; Gardin G; Pronzato P; Camoriano A; Merlini L; Naso C; Rosso M; Barone C; Nascimben O; Ianniello G
Ann N Y Acad Sci; 1993 Nov; 698():349-56. PubMed ID: 8279774
[No Abstract] [Full Text] [Related]
64. Phase II evaluation of cisplatin and WR2721 for refractory metastatic breast cancer.
Ramnath N; LoRusso P; Simon M; Martino S
Am J Clin Oncol; 1997 Aug; 20(4):368-72. PubMed ID: 9256891
[TBL] [Abstract][Full Text] [Related]
65. Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease.
Hirai I; Tanese K; Nakamura Y; Ishii M; Kawakami Y; Funakoshi T
Oncologist; 2019 Jun; 24(6):e394-e396. PubMed ID: 30846514
[TBL] [Abstract][Full Text] [Related]
66. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.
Bajetta E; Rimassa L; Carnaghi C; Seregni E; Ferrari L; Di Bartolomeo M; Regalia E; Cassata A; Procopio G; Mariani L
Cancer; 1998 Jul; 83(2):372-8. PubMed ID: 9669822
[TBL] [Abstract][Full Text] [Related]
67. Anemia requiring transfusion in breast cancer patients on dose-dense chemotherapy: Prevalence, risk factors, cost and effect on disease outcome.
Sharma P; Georgy JT; Andrews AG; John AO; Joel A; Chacko RT; Premkumar PS; Singh A
Support Care Cancer; 2022 Jun; 30(6):5519-5526. PubMed ID: 35314996
[TBL] [Abstract][Full Text] [Related]
68. Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
DiBella NJ; Garfield D; Fink K; Anderson P; Speer J; Murphy J
Oncology; 1984; 41(1):1-3. PubMed ID: 6422372
[TBL] [Abstract][Full Text] [Related]
69. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
Amadori D; Frassineti GL; De Matteis A; Mustacchi G; Santoro A; Cariello S; Ferrari M; Nascimben O; Nanni O; Lombardi A; Scarpi E; Zoli W
Breast Cancer Res Treat; 1998 Jun; 49(3):209-17. PubMed ID: 9776504
[TBL] [Abstract][Full Text] [Related]
70. Mitomycin-C and lonidamine as second-line therapy for colorectal cancer: a phase II study.
Zaniboni A; Meriggi F; Alghisi A; Mutti S; Distefano L; Rizzi A; Bettini L; Simoncini E; Marpicati P; Montini E
Tumori; 1995; 81(6):435-7. PubMed ID: 8804471
[TBL] [Abstract][Full Text] [Related]
71. Combination chemotherapy with epirubicin and cisplatin in ovarian carcinoma.
Fuith LC; Bazzanella A; Hetzel H
Arch Gynecol Obstet; 1988; 244(1):15-21. PubMed ID: 3240002
[TBL] [Abstract][Full Text] [Related]
72. Epirubicin treatment of advanced breast carcinoma with the weekly low-dose regimen.
Beretta G; Locatelli C; Tabiadon D; Labianca R; Fraschini P; Luporini G
Oncology; 1987; 44(1):6-12. PubMed ID: 2436124
[TBL] [Abstract][Full Text] [Related]
73. High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study.
Fountzilas G; Skarlos D; Pavlidis NA; Makrantonakis P; Tsavaris N; Kalogera-Fountzila A; Giannakakis T; Beer M; Kosmidis P
Tumori; 1991 Jun; 77(3):232-6. PubMed ID: 1862551
[TBL] [Abstract][Full Text] [Related]
74. Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study.
Atiba JO; Green SJ; Hynes HE; Osborne CK; Miller TP; Davidner M
Invest New Drugs; 1994; 12(2):129-32. PubMed ID: 7860229
[TBL] [Abstract][Full Text] [Related]
75. A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma.
Saglam S; Aykan NF; Sakar B; Gulluoglu M; Balik E; Karanlik H
J Gastrointest Oncol; 2011 Mar; 2(1):19-26. PubMed ID: 22811823
[TBL] [Abstract][Full Text] [Related]
76. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
Mansi JL; de Graeff A; Newell DR; Glaholm J; Button D; Leach MO; Payne G; Smith IE
Br J Cancer; 1991 Sep; 64(3):593-7. PubMed ID: 1911204
[TBL] [Abstract][Full Text] [Related]
77. Phase I study of thymidine (dThd) and cisplatin (DDP) given in combination.
Chiuten DF; Valdivieso M; Benvenuto JA; Drewinko B; Bedikian A; Bodey GP
Am J Clin Oncol; 1986 Apr; 9(2):129-31. PubMed ID: 3717079
[TBL] [Abstract][Full Text] [Related]
78. The pharmacokinetics of oral lonidamine in breast and lung cancer patients.
Newell DR; Mansi J; Hardy J; Button D; Jenns K; Smith IE; Picollo R; Catanese B
Semin Oncol; 1991 Apr; 18(2 Suppl 4):11-7. PubMed ID: 2031191
[TBL] [Abstract][Full Text] [Related]
79. Phase II study of 4-epirubicin, etoposide and cisplatin as neoadjuvant chemotherapy in locally advanced breast cancer.
Costa MA; Lamarca JE; Bader GR
Eur J Cancer; 1994; 30A(6):891. PubMed ID: 7917557
[No Abstract] [Full Text] [Related]
80. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer.
Jones RD; Kerr DJ; Harnett AN; Rankin EM; Ray S; Kaye SB
Br J Cancer; 1990 Jul; 62(1):133-5. PubMed ID: 2390473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
